Comparing new red blood cell medicine to Eprex in healthy men
This trial tests a new medicine (NANOKINE) that helps your body make red blood cells, compared to a well-known drug (Eprex). It is for healthy men to see how safe it is and how it works in the body. If you qualify, you might help develop a better option for treating anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 45 years old.
- Your weight is between 50 and 70 kg (about 110-154 pounds).
- You are generally healthy, with no major ongoing illnesses.
- Your blood tests meet certain ranges for hemoglobin, vitamin B12, iron, and other markers.
- You have not used erythropoiesis-stimulating agents (ESAs) or immunoglobulins in the last 3 months.
- You do not have a history of alcohol or drug abuse, and you do not smoke more than 10 cigarettes a day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new erythropoietin (a medicine that helps your body make red blood cells) and compares it to an approved version called Eprex. It is for healthy adults to see how the two medicines work in the body and if they are safe.
This study tests two medicines, luspatercept and epoetin, to see which one helps the body make more red blood cells after a stem cell transplant. If you have low red blood cell counts after your transplant, this trial may help improve your energy and reduce the need for transfusions.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study compares two similar medicines used to treat anemia (low red blood cells) in people with advanced kidney disease who are on dialysis. The goal is to see if both work equally well.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This study compares two anemia medicines for people with chronic kidney disease (CKD) who are not on dialysis. It aims to find a more convenient pill option (daprodustat) versus a commonly used injection (epoetin alfa).
Hear when a new Pharmacokinetics and Pharmacodynamics in Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.